Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression

Zhang, Chuan; Huang, Yue; Jiang, Long; Yao, Xiaochen; Wang, Jun; Zang, Shimin; Qu, Wei; Wang, Rui

doi:10.3892/ol.2018.9795

Cited by 9 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Determination of chromogranin A in blood serum, whose level correlates with the degree of the ECL cells' hyperplasia, can be considered as an auxiliary marker for assessing the risk of NET formation [34][35][36][37]. The sensitivity and specificity of chromogranin A as a possible marker of NET is low; therefore, its determination result should be assessed taking into account the clinical picture and the histological examination data.…”

Section: Laboratory Methodsmentioning

confidence: 99%

Chronic Autoimmune Gastritis: Modern Diagnostic Principles

et al. 2021

View full text Add to dashboard Cite

This article summarizes and systematizes the available data from the literature on chronic autoimmune gastritis (CAG) in order to increase the awareness of specialists about the modern possibilities for diagnosing the disease, including its early stages. The clinical manifestation of the disease includes possible variants such as gastrointestinal, hematological (first of all, the formation of iron deficiency and B12-deficiency anemia), and neurological variants. Patients with chronic autoimmune gastritis are characterized by comorbidity with other autoimmune diseases. In this paper, data on the most informative serological markers for the diagnosis of CAG, as well as laboratory tests to detect micronutrient deficiencies, information on the characteristic changes in the gastric mucosa, and the prognosis of the disease, are presented. The diagnosis of CAG should be based on a multidisciplinary approach that combines a thorough analysis of a patient’s complaints with a mandatory assessment of nutritional status, as well as the results of serological, endoscopic, and histological research methods.

show abstract

Section: Laboratory Methodsmentioning

confidence: 99%

Chronic Autoimmune Gastritis: Modern Diagnostic Principles

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Serum CgA is considered as the diagnostic biomarker for gastroenteropancreatic neuroendocrine neoplasms and has been utilized in clinical applications (Pulvirenti et al, 2019; Zhang et al, 2019). However, it has not been found effective as a biomarker for diagnosis or management of bronchopulmonary neuroendocrine tumors/neoplasms (Matar et al, 2019).…”

Section: Types Of Biomarkersmentioning

confidence: 99%

Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values

Dhama

Latheef

Dadar

et al. 2019

Front. Mol. Biosci.

221

172

View full text Add to dashboard Cite

Various internal and external factors negatively affect the homeostatic equilibrium of organisms at the molecular to the whole-body level, inducing the so-called state of stress. Stress affects an organism's welfare status and induces energy-consuming mechanisms to combat the subsequent ill effects; thus, the individual may be immunocompromised, making them vulnerable to pathogens. The information presented here has been extensively reviewed, compiled, and analyzed from authenticated published resources available on Medline, PubMed, PubMed Central, Science Direct, and other scientific databases. Stress levels can be monitored by the quantitative and qualitative measurement of biomarkers. Potential markers of stress include thermal stress markers, such as heat shock proteins (HSPs), innate immune markers, such as Acute Phase Proteins (APPs), oxidative stress markers, and chemical secretions in the saliva and urine. In addition, stress biomarkers also play critical roles in the prognosis of stress-related diseases and disorders, and therapy guidance. Moreover, different components have been identified as potent mediators of cardiovascular, central nervous system, hepatic, and nephrological disorders, which can also be employed to evaluate these conditions precisely, but with stringent validation and specificity. Considerable scientific advances have been made in the detection, quantitation, and application of these biomarkers. The present review describes the current progress of identifying biomarkers, their prognostic, and therapeutic values.

show abstract

“…Thus, we take into consideration CgA, a marker secreted by neuroendocrine cells and useful in the follow-up of low-grade NETs. It generally correlates positively with tumor burden, treatment response and prognosis ( 13 ). It should be noted that cells from higher-grade NETs can lose the ability of secreting CgA due to their loss of differentiation resulting in widely variable values of CgA ( 14 ).…”

Section: Discussionmentioning

confidence: 99%

Bone metastases from neuroendocrine tumors: clinical and biological considerations

Scopel

Carlo

Bergamo

et al. 2022

Endocrine Connections

View full text Add to dashboard Cite

We considered 351 patients affected by neuroendocrine tumors, followed at the University Hospital of Padua and at the Veneto Oncological Institute. Of these, 72 (20.5%) suffered from bone metastases. The sample was divided according to the timing of presentation of bone metastases into synchronous (within 6 months of diagnosis of primary tumor) and metachronous (after 6 months). We collected data on the type and grading of the primary tumor, and on the features of bone metastases. Our analysis shows that the group of synchronous metastases generally presents primary tumors with a higher degree of malignancy rather than the ones of the metachronous group. This is supported by the finding of a Ki-67 level in GEP-NETs, at the diagnosis of bone metastases, significantly higher in the synchronous group. Moreover, in low-grade NETs, Chromogranin A values are higher in the patients with synchronous metastases, indicating a more burden of disease. The parameters of phospho-calcium metabolism are within the normal range, and we do not find significant differences between the groups. Serious bone complications are not frequent and are not correlated with the site of origin of the primary tumor. From the analysis of the survival curves of the total sample, a cumulative survival rate of 33% at 10 years emerges. The average survival is 80 months, higher than what reported in the literature, while the median is 84 months. In our observation period, synchronous patients tend to have a worse prognosis than metachronous ones with 52-months survival rates of 58% and 86%.

show abstract

Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression

Cited by 9 publications

References 22 publications

Chronic Autoimmune Gastritis: Modern Diagnostic Principles

Chronic Autoimmune Gastritis: Modern Diagnostic Principles

Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values

Bone metastases from neuroendocrine tumors: clinical and biological considerations

Contact Info

Product

Resources

About